The Latest Breaking News from Mustang

These cars have defined an era and made the world a better place for car nuts.

Thomas Randle and Andre Heimgartner walked away from a high-speed crash while Shane van Gisbergen took a clean sweep in Supercars action at Tailem Bend.

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193  in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Ford is recalling nearly 50,000 Mach-E electric SUVs due to a faulty battery contactor that could leave the car inoperable. It has issued a software update.

The BMW has a Tesla powertrain.

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Mustang Bio’s (NASDAQ: MBIO) lead drug MB-106 for the treatment of Waldenstrom macroglobulinemia (WM), a rare type of B-cell non-Hodgkin lymphoma (B-NHL).

SMU College Football Preview 2022: Team breakdown, season prediction, keys to the campaign, and what you need to know

The Mini will need a miracle to win.

A 450-hp Shelby-tuned Mustang will also be available to rent as a coupe or convertible.

PONTIAC, Michigan — I like Skittle-colored Mustangs. Red, blue, orange, yellow. Especially yellow. The bright color turns heads on Woodward Avenue, accentuates the muscular hips, stands out against the snow.

Mustang Bio Inc (NASDAQ:MBIO) announced updated interim data from the ongoing Phase 1/2 trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL).  MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center. The data demonstrated…